Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology | Endocrinology | Family Medicine
Clinical Trials: Pancreatic Cancer
A listing of clinical trials currently looking for volunteers to enroll in Pancreatic Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Birmingham : Birmingham Hematology and Oncology Associates, LLC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Birmingham : University of Alabama Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Mobile : University of South Alabama Mitchell Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Mobile : University of South Alabama Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Arizona
Gilbert : Banner Healthcare
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Scottsdale : Scottsdale Healthcare
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Tucson : Arizona Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Arkansas
California
Bellflower : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Duarte : City of Hope
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer
Duarte : City of Hope
Clinical Value of Molecular Profiling of Pancreatic Cancer Surgical Patients
Duarte : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Encinitas : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Los Angeles : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Orange : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
San Francisco : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Santa Maria : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Alhambra : Central Hematology Oncology Medical Group, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Bakersfield : Comprehensive Blood and Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Duarte : City of Hope National Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Fresno : California Cancer Associates for Research and Excellence (CCARE)
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Long Beach : Pacific Shores Medical Group
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Los Angeles : UCLA Community Oncology Practice
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Los Angeles : Cedars-Sinai Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Orange : Hematology Oncology Medical Group of Orange County, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Palo Alto : Stanford University Medical Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Palo Alto : Stanford Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Rancho Cucamonga : Wilshire Oncology Medical Group, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Sacramento : Sutter Institute for Medical Research Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
San Diego : Sharp Health Care
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
San Francisco : California Pacific Medical Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
San Francisco : California Pacific Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
San Jose : San Jose Medical Group
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Colorado
Aurora : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Aurora : University of Colorado Denver
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
Aurora : University of Colorado Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Grand Junction : Saint Mary's Regional Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Connecticut
Stamford : Hematology Oncology Associates, PC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Stamford : Stamford Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Delaware
Newark : Christiana Care Health Services Helen Graham Cancer Center
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
District of Columbia
Florida
Boynton Beach : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Tampa : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Boca Raton : Boca Raton Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Gainesville : University of Florida Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Jacksonville : Mayo Clinic Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Lakeland : Lakeland Regional Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tampa : Florida Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Tampa : MOFFITT Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tampa : USF Tampa General Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Georgia
Atlanta : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Savannah : Memorial University Medical Center
ACOSOG Z5041 : A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma.
Savannah : Memorial University Medical Center
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
View More »
Atlanta : Georgia Cancer Specialists, P.C.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Illinois
Chicago : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Chicago : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Arlington Heights : Illinois Cancer Specialists Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Chicago : Northwestern University
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Chicago : University of Chicago Medical Center
Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
Chicago : University of Chicago Comprehensive Cancer Center
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Chicago : Northwestern University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Evanston : Northshore University Health Systems Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Skokie : Edward H. Kaplan, MD and Associates Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Indiana
Goshen : Goshen Center for Cancer Care
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Indianapolis : Investigative Clinical Research of Indiana, LLC Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Indianapolis : Indiana University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Iowa
Iowa City : University of Iowa Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Kansas
Overland Park : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Wichita : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Westwood : University of Kansas Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Kentucky
Crestview Hills : Oncology Hematology Care, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Louisville : James Graham Brown Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Louisville : University of Louisville Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Louisiana
Baton Rouge : Mary Bird Perkins Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
New Orleans : Ochsner Cancer Institute Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Maryland
Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Baltimore : University of Maryland Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Bethesda : National Cacner Institue
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Massachusetts
Boston : Massachusetts General Hospital Dept. of Mass General Hospital
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Boston : Beth Israel Deaconess Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Boston : Massachusetts General Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Boston : Dana-Farber Cancer Institute Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
View More »
Burlington : Lahey Clinic Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Michigan
Ann Arbor : University of Michigan Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Detroit : Henry Ford Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Detroit : Karmanos Cancer Institute
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Grand Rapids : St. Mary's Trinity Healthcare
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
View More »
Kalamazoo : West Michigan Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Royal Oak : Beaumont Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Southfield : Providence Cancer Center Oncology and Hematology Care Clinic-Eastside Portland
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Minnesota
Minneapolis : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Minneapolis : Virginia Piper Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Minneapolis : Virginia Piper Cancer Institute Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Rochester : Mayo Clinic Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Mississippi
Tupelo : Hematology and Oncology Associates at BridgePoint
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Missouri
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Columbia : University of Missouri Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Saint Joseph : Saint Joseph Oncology, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Saint Louis : Washington University School of Medicine
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
View More »
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
St. Louis : Washington University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Montana
Missoula : Montana Cancer Institute Foundation c/o Montana Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Nebraska
Omaha : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Omaha : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Omaha : University of Nebraska Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Nevada
Henderson : Comprehensive Cancer Centers of Nevada
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
New Mexico
Albuquerque : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Albuquerque : New Mexico Cancer Care Alliance
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Albuquerque : University of New Mexico Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
A Phase 2 Study of REOLYSIN in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Bronx : Biomedical Research Alliance of New York
Pancreatic Cancer - Adults
Lake Success : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Lake Success : Biomedical Research Alliance of New York
Pancreatic Cancer
Syracuse : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
New York : Beth Israel Comprehensive Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
New York : Saint Luke's-Roosevelt Hospital Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
New York : Memorial Sloan Kettering Cancer Center MSKCC - SC
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
New York : Mount Sinai Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
New York : Memorial Sloan Kettering Cancer Center
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
North Carolina
Charlotte : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Durham : Duke University Medical Center, Comprehensive Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Durham : Duke University Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
High Point : Emerywood Hematology and Oncology
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Winston-Salem : Wake Forest Baptist Health Comprehensive Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Ohio
Blue Ash : Oncology Hematology Care, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Cincinnati : University of Cincinnati Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Cleveland : University Hospitals Case Western Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Cleveland : University Hospitals
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Columbus : Ohio State University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Oklahoma
Oklahoma City : University of Oklahoma Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Oregon
Portland : Oregon Health and Science University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Pennsylvania
Bethlehem : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Philadelphia : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Pittsburgh : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Bethlehem : St. Luke's Hospital and Health Network Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Harrisburg : PinnacleHealth
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Hershey : Penn State Hershey Cancer Institute Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Philadelphia : Kimmel Cancer Center at Jefferson University
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Philadelphia : Fox Chase Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Philadelphia : Thomas Jefferson University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Philadelphia : University of Pennsylvania Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Pittsburg : University of Pittsburg Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Pittsburgh : Hillman Cancer Center
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Willow Grove : Abington Hematology Oncology Associates, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Rhode Island
Providence : Roger Williams Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
South Carolina
Charleston : Charleston Hematology Oncology Associates, PA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Columbia : South Carolina Oncology Associates
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Greenville : Institute of Translational Oncology Research
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Greenville : Cancer Center of the Carolinas Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tennessee
Knoxville : Tennessee Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Nashville : Tennessee Oncology, PLLC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Texas
San Antonio : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Corpus Christi : Coastal Bend Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Dallas : University of Texas Southwestern Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Fort Worth : Center for Cancer and Blood Disorders, PC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Houston : UT MD Anderson Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Houston : Baylor College of Medicine Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Houston : Ben Taub Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Houston : The Methodist Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Lubbock : Joe Arrington Cancer Research and Treatment Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Lubbock : Joe Arrington Cancer Research and Treatment Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
San Antonio : University of Texas Health Sciences Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Utah
Salt Lake City : Utah Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman UT
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Virginia
Charlottesville : University of Virginia Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Fairfax : Virginia Cancer Specialists, PC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Lynchburg : Lynchburg Hematology-Oncology Clinic, Inc. Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Norfolk : VA Oncology Associates
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Richmond : Virginia Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
View More »
Richmond : Virginia Commonwealth University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Washington
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
ACOSOG-Z5041: Ph2 of Neoadjuvant and Adjuvant Gemcitabine Hydrochloride and Erlotinib Hydrochloride in pts + Resectable Adenocarcinoma of the Pancreas Undergoing Pancreatectomy.
Wisconsin
Australia
Blacktown : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Footscray : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Frankston, VIC : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Liverpool : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Parkville : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Tweed Heads : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Adelaide : Royal Adelaide Hospital
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Box Hill : Box Hill Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Camperdown : Royal Prince Alfred Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Heidelberg : The Austin Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Nedlands : Sir Charles Gairdner Hospital and University of Western Australia
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Woodville South : The Queen Elizabeth Hospital
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Austria
Graz : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Innsbruck : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Wien : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Wien :
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Belgium
Brussels : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Gent : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Leuven : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Antwerp : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Canada
China
Shanghai : Shanghai Changhai Hospital
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Tianjin : Tianjin Medical University Cancer Institute and Hospital
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Cyprus
Nicosia : Cyprus Oncology Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Czech Republic
Olomouc : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Pardubice : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Prague 8 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Zlin : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
France
Angers : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Besançon cedex : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Clermont Ferrand cedex 1 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Clichy : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Lille : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Lyon cedex 03 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Paris cedex 14 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Saint-Priest-en-Jarez : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Saint-Priest-en-Jarez cedex 2 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Clermont-Ferrand : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Lomme : Hôpital Saint-Philibert
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Lyon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Lyon : Hôpital Jean Mermoz
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Marseille : Institut Paoli Calmettes
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Germany
Bochum : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Hamburg : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Hamburg : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Jena : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Köln : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Köln : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Lemgo : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Mannheim : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
München : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Tübingen : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Friedrichshafen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Leipzig : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Marburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Reutlingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Saarbrucken : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Hungary
Budapest : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Budapest : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Gyor : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Pecs : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Ireland
Dublin 24 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Dublin 4 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Dublin 7 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Dublin 9 : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Israel
Beer Sheva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Jerusalem : Hadassah Medical Organization
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas
Jerusalem : Shaare Zedek Medical Center
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas
Petah Tiqva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
View More »
Ramat Gan : Sheba Medical Center
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas
Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Italy
Ancona : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Bologna : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Chieti : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Milan : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Reggio Emilia : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Udine : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Bologna : Azienda Ospedaliero-Universitaria di Bologna
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Confreria : A.O. Santa Croce e Carle, Struttura Complessa di Oncologia Medica
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Monza : Azienda Ospedaliera San Gerardo Struttura Complessa Oncologia Medica
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Novara : AOU Maggiore della Carità
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Verona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Japan
Gifu : Gifu University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Onomichi : Onomichi General Hospital
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Sapporo : Teine-Keijinkai Hospital
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Tokyo : The University of Tokyo
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Tokyo : Toho University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
View More »
Tokyo : Tokyo Medical University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Ube : Yamaguchi University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Korea, Republic of
Bucheon : Soon Chun Hyang University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Cheonan : Soon Chun Hyang University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Daegu : Catholic University of Daegu School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Goyang-si : NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
Incheon : Inha University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
View More »
Seoul : Gangnam Severance Hospital
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Suwon : Ajou University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Netherlands
Amsterdam : VU University Medical Center
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
New Zealand
Christchurch : Christchurch Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Hamilton : Waikato Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Norway
Poland
Jelenia Gora : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Lublin : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Olsztyn : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Romania
Bucharest : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Cluj-Napoca : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Craiova : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
IASI : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Russia
Chelyabinsk : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Kazan : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Krasnodar : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Moscow : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Voronezh : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Saudi Arabia
Riyadh : National Guard Health Affairs
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
Singapore
Outram Road : Singapore General Hospital
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
Spain
Alicante : Hospital General de Alicante
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Asturias : Medical Oncology Department, Central University Hospital of Asturias
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Barcelona : Novartis Investigative Site
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
View More »
Madrid : START Madrid
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Madrid : Hospital Gregorio Marañon
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Pozuelo De Alarcon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Valencia : Department of Medical Oncology, Hospital Universitari La Fe,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Valencia : Instituto Valenciano de Oncologia
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Zaragoza : Hospital Miguel Servet
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
United Kingdom
Chelmsford, Essex : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Edinburgh : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Glasgow : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Hull : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Leeds : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Liverpool : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
London : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
London : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Maidstone : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Northwood : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Salisbury : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Sutton : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
View More »
Blackburn : Royal Blackburn Hospital
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Bournemouth : The Royal Bournemouth Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Bradford : Bradford Royal Infirmary
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Cambridge : Cambridge University Hospitals NHS Foundation Trust
HYPAZ: Hypertension Induced by Pazopanib
Cardiff : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Cardiff : Velindre Cancer Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Dundee : Ninewells Hospital,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Edinburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Guildford : Royal Surrey County Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Liverpool : Clatterbridge Centre for Oncology
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Liverpool : Royal Liverpool University Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Liverpool : Novartis Investigative Site
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
London : Guy's and St Thomas' Hospital NHS Trust
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
London : The London Clinic Cancer Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
London : Mount Vernon Cancer Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
London : Guys & St Thomas Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Manchester : The Christie Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Middlesbrough : James Cook University Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Nottingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Nottingham : Nottingham City Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Peterborough : Peterbrough City Hospital, Haematology/Oncology Dept,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Sheffield : Weston Park Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Skipton : Airedale General Hospital
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Southampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Sutton : The Royal Marsden NHS Trust
A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
USA
Liverpool : Research Site
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
